Typhoid Conjugate Vaccine (TCV)

Typhoid (enteric fever) caused by Salmonella typhi is endemic in India with millions of cases annually. The Typhoid Conjugate Vaccine (TCV) provides longer-lasting protection than the older Vi polysaccharide vaccine. TCV was approved by WHO in 2018 and introduced in several states under India's immunization programme.

The Typhoid Conjugate Vaccine (TCV) is recommended for 6 months–45 years; recommended at 9-12 months and school-entry. It falls under the Adolescent vaccine category. Consult your doctor to confirm if this vaccine is right for you based on your health history and existing immunity.

The Typhoid Conjugate Vaccine (TCV) has an efficacy of 81.6% in a clinical trial; >87% in field conditions. This means it provides significant protection against Typhoid fever (Enteric fever) caused by Salmonella Typhi. Efficacy may vary based on age, health status, and the specific strain encountered.

Common side effects include: Injection site pain and redness (common); mild fever; headache; fatigue. Serious adverse events are rare.. These are typically mild and resolve within 1–3 days. Serious allergic reactions are rare — if you experience difficulty breathing, hives, or rapid heartbeat after vaccination, seek emergency care immediately.

The Typhoid Conjugate Vaccine (TCV) should be avoided by: Acute febrile illness (defer); hypersensitivity to tetanus toxoid or vaccine components. Safe in pregnancy (consult doctor).. Always inform your healthcare provider of your full medical history before vaccination.

The Typhoid Conjugate Vaccine (TCV) typically costs ₹500–₹1,500 in India. Government health centres may offer it free or at subsidised prices for eligible age groups. Private hospitals and clinics may charge differently. Additional fees may apply for administration.